Zoetis Cuts 2022 Adjusted. Earnings Guidance, Lowers High-End of Sales Range
August 04 2022 - 08:06AM
Dow Jones News
By Will Feuer
Zoetis Inc. cut its full-year adjusted earnings guidance and
lowered the high-end of its range for sales, citing negative
effects from recent changes to foreign-exchange rates.
The animal-medicine company, spun off by Pfizer Inc. in 2013,
said it now expects adjusted earnings of between $4.97 a share and
$5.05 a share, down from its prior guidance of $4.99 a share to
$5.09 a share.
Full-year revenue is expected to be between $8.225 billion and
$8.325 billion, narrowed from $8.225 billion to $8.375 billion.
Unadjusted earnings are expected to be between $4.65 a share and
$4.75 a share, narrowed from a range of $4.65 a share to $4.77 a
share.
Write to Will Feuer at Will.Feuer@wsj.com
(END) Dow Jones Newswires
August 04, 2022 07:51 ET (11:51 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
Pfizer (NYSE:PFE)
Historical Stock Chart
From Feb 2024 to Mar 2024
Pfizer (NYSE:PFE)
Historical Stock Chart
From Mar 2023 to Mar 2024